RT Book, Section
A1 Damon, Lloyd E.
A1 Andreadis, Charalambos Babis
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
SR Print(0)
ID 1175800696
T1 Hairy Cell Leukemia
T2 Current Medical Diagnosis & Treatment 2021
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260469868
LK accessmedicine.mhmedical.com/content.aspx?aid=1175800696
RD 2023/06/02
AB Key  Clinical  Updates  in  Hairy  Cell  LeukemiaMoxetumomab  pasudotox  is  a  recombinant  CD22-targeting  immunotoxin  recently  approved  for  patients  with  refractory  hairy  cell  leukemia.  It  has  shown  a  durable  complete  response  rate  of  31%  in  the  pivotal  trial.